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Introduction
One well-characterized inhibitor of axonal growth is myelin-
  associated glycoprotein (MAG), an Ig superfamily member ex-
pressed by myelinating glia (Filbin, 2003). In the central nervous 
system (CNS), MAG is localized to periaxonal oligodendroglial 
membranes of myelin sheaths and participates in axon–glia in-
teractions (Quarles, 2007). Germline ablation of MAG is not 
 suffi  cient to promote axonal regeneration in vivo (Bartsch et al., 
1995), but acute inactivation of MAG in retina-optic nerve cul-
tures leads to enhanced optic nerve regeneration (Wong et al., 
2003). In addition to its role as a regulator of neuronal growth, 
MAG has also been shown to regulate the long-term stability 
and integrity of axon-myelin associations in the optic nerve 
(Bartsch et al., 1997) and other fi  ber systems (Pan et al., 2005). 
The mechanisms that enable MAG to exert its pleiotropic effects 
are not well understood and are only now starting to be defi  ned.
MAG is a member of the Siglec family of sialic acid–
binding Ig-lectins with an ectodomain comprised of fi  ve Ig-like 
repeats (Crocker, 2002). MAG binds to the neuronal cell surface 
and inhibits growth in a sialic acid–dependent Vibrio cholerae 
neuraminidase (VCN)–sensitive manner (Kelm et al., 1994; 
DeBellard et al., 1996). Select gangliosides, including GD1a 
and GT1b, support MAG binding in a sialic acid–dependent 
manner, and postnatal cerebellar granule neurons (CGNs) iso-
lated from mice lacking complex gangliosides are substantially 
less inhibited by MAG, indicating that gangliosides play an 
  important role in MAG inhibitory neuronal responses (Vyas 
and Schnaar, 2001; Vyas et al., 2002). A soluble fusion protein 
of MAG comprised of the fi  rst three Ig repeats, MAG(1–3)-Fc, 
binds to neurons in a sialic acid–dependent manner but is not 
suffi  cient to bring about inhibition (Tang et al., 1997). This 
suggests that sialic acid–independent sites located in Ig repeats 
4 or 5 of the MAG ectodomain are important for neurite out-
growth inhibition.
More recently, MAG has been found to interact with mem-
bers of the Nogo receptor family, including neuronal Nogo66 
receptor (NgR)-1 and NgR2 (Domeniconi et al., 2002; Liu et al., 
2002; Venkatesh et al., 2005). NgR1 has been proposed to func-
tion as the ligand-binding component of a tripartite NgR1–
p75
NTR–Lingo-1 receptor complex that signals MAG inhibition 
(Wang et al., 2002; Yamashita et al., 2002; Mi et al., 2004). 
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euronal Nogo66 receptor-1 (NgR1) binds the 
myelin inhibitors NogoA, OMgp, and myelin-
  associated glycoprotein (MAG) and has been 
proposed to function as the ligand-binding component of 
a receptor complex that also includes Lingo-1, p75
NTR, or 
TROY. In this study, we use Vibrio cholerae neuraminidase 
(VCN) and mouse genetics to probe the molecular com-
position of the MAG receptor complex in postnatal retinal 
ganglion cells (RGCs). We ﬁ  nd that VCN treatment is not suf-
ﬁ  cient to release MAG inhibition of RGCs; however, it does 
attenuate MAG inhibition of cerebellar granule neurons. 
Furthermore, the loss of p75
NTR is not sufﬁ  cient to re-
lease MAG inhibition of RGCs, but p75
NTR−/− dorsal 
root ganglion neurons show enhanced growth on MAG 
compared to wild-type controls. Interestingly, TROY is 
not a functional substitute for p75
NTR in RGCs. Finally, 
NgR1
−/− RGCs are strongly inhibited by MAG. In the 
presence of VCN, however, NgR1
−/− RGCs exhibit en-
hanced neurite growth. Collectively, our experiments 
  reveal distinct and cell type–speciﬁ   c mechanisms for 
MAG-elicited growth inhibition.
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Upon MAG binding to the neuronal cell surface, p75
NTR under-
goes α- and γ-secretase–dependent proteolytic cleavage, and 
processing of p75
NTR is important for RhoA activation and sub-
sequent inhibition of neurite outgrowth (Domeniconi et al., 
2005). Similar to p75
NTR, the structurally related protein TROY 
associates with NgR1 and Lingo- 1. In the mature CNS, p75
NTR 
expression is restricted, and TROY has been proposed to serve 
as a functional substitute in neurons that lack p75
NTR (Park 
et al., 2005; Shao et al., 2005). In spite of the growing number 
of cell surface receptor components implicated in MAG inhibi-
tion, their role and relative contribution to growth inhibition in 
different cell types has not yet been examined. In this study, we 
provide evidence that MAG uses distinct and cell type–specifi  c 
mechanisms to signal growth inhibition in different neuronal 
cell types, a fi  nding that may have important implications for 
the development of strategies aimed at promoting neural repair 
after CNS injury.
Results and discussion
Loss of terminal sialic acids 
attenuates MAG inhibition in a 
cell type–speciﬁ  c manner
Neurite outgrowth of postnatal retinal ganglion cells (RGCs), 
a population of myelinated CNS neurons, is strongly inhibited 
by MAG. On CHO-MAG feeder cells, Thy-1–immunopanned 
RGCs from postnatal day (P) 7–10 rat retina are strongly inhib-
ited (neurite length = 10.2 ± 0.6 μm) compared with control 
CHO cocultures (neurite length = 26.0 ± 1.6 μm). To examine 
whether sialoglycans are important for MAG-mediated inhibition 
of RGCs, cultures were treated with increasing concentra-
tions of VCN to remove cell surface terminal sialic acids (Fig. 1, 
A and B). Interestingly, neurite length on CHO-MAG cells 
is not signifi  cantly enhanced in the presence of VCN either at 
2.5 (11.6 ± 0.7 μm; P = 0.427) or 5.0 mU/ml (11.5 ± 1.3 μm; 
P = 0.569) of enzyme when compared with CHO-MAG control 
cultures not treated with VCN (10.2 ± 0.6 μm). Increasing 
the VCN dose to 7.5 mU/ml inhibits the growth of RGCs and 
results in signifi  cantly reduced neurite length on control CHO 
cells (20.9 ± 1.9 μm; P = 0.012). Together, our results suggest 
that sialoglycan-independent mechanisms are suffi  cient for MAG 
inhibition of RGCs.
As an additional cell type to examine whether the loss of 
terminal sialic acids is important for MAG inhibition, we used 
rat P7–8 CGNs. Neurite outgrowth of CGNs cultured on CHO-
MAG cells (19.0 ± 0.8 μm) is strongly inhibited compared 
with CGNs grown on CHO cells (38.6 ± 1.3 μm). Consistent 
with a previous study (Vyas et al., 2002), we found that in the 
presence of 7.5 mU/ml VCN, neurite length on CHO-MAG is 
signifi  cantly increased (25.0 ± 1.3 μm) compared with un-
treated CGNs on CHO-MAG (19.0 ± 0.8 μm; P < 0.001). 
Neurite outgrowth on CHO cells is not signifi  cantly altered in the 
presence (38.9 ± 1.6 μm) or absence of VCN (38.6 ± 1.3 μm; 
P = 0.838). Increasing the VCN dose to 15 mU/ml did not lead 
to any further promotion of the neurite growth of CGNs on 
CHO-MAG (Fig. 1, C and D; and not depicted). To assess VCN 
activity, we took advantage of a previous observation that 
NgR1 and NgR2 show a VCN-dependent drop in molecular 
weight (Venkatesh et al., 2005). Because of the limited yield of 
immunopanned RGCs, hippocampal neurons were treated for 
Figure 1. Cell  type–speciﬁ   c requirement of terminal sialic 
acids for MAG inhibition. (A–D) P7–10 rat retinal (RGCs; A) 
and P7–8 rat cerebellar (CGNs; C) neurons were plated on 
CHO (white bars) or CHO-MAG (black bars) feeder layers. 
VCN was added to the culture medium at the indicated con-
centrations. (B and D) Quantiﬁ  cation of the neurite length of 
TuJ1-stained cultures. The number of neurites measured for 
each condition is indicated in parentheses. Results are pre-
sented as mean neurite length ± SEM (error bars). One-way 
analysis of variance with post-hoc pairwise comparisons 
(Holm-Sidak method). *, P < 0.001. (E) To assess whether 
VCN treatment of primary neurons results in a loss of terminal 
sialic acids, hippocampal neurons treated for 4 h with 2.5 
mU/ml VCN were lysed, separated by SDS-PAGE, and sub-
jected to anti-NgR1 immunoblotting. In the absence of VCN, 
NgR1 runs at an apparent molecular mass of 65 kD. Upon 
VCN treatment, an  3.0-kD drop in the molecular mass of 
NgR1 is observed, conﬁ  rming that terminal sialic acids were 
removed successfully. Bars, 50 μm.ANALYSIS OF THE MAG RECEPTOR • VENKATESH ET AL. 395
4 h with 2.5 mU/ml VCN. Immunoblotting of lysed cells 
showed an  3-kD shift in the molecular mass of NgR1, indi-
cating that terminal sialic acid moieties were removed success-
fully (Fig. 1 E). In addition, we show that VCN treatment of 
feeder cells does not change neuronal growth behavior (Fig. 
S1, A and B; available at http://www.jcb.org/cgi/content/full/
jcb.200702102/DC1). Together, our results provide evidence 
for a neuronal cell type–specifi  c requirement of terminal sialic 
acids for MAG inhibition.
Neuronal cell type–speciﬁ  c requirement 
of p75
NTR for MAG inhibition
To begin to address whether previously identifi  ed protein com-
ponents of the MAG receptor complex are necessary for neurite 
outgrowth inhibition, RGCs from wild-type and p75
NTR-
 defi  cient mice were assayed for MAG responsiveness (Fig. 2). 
On CHO cells, the neurite length of wild-type (33.8 ± 1.8 μm) 
and p75
NTR−/− RGCs (33.1 ± 1.7 μm) is indistinguishable. 
Furthermore, on CHO-MAG cells, the neurite length of wild-
type (15.0 ± 0.9 μm) and p75
NTR−/− RGCs (15.2 ± 1.0 μm) is 
very similar (Fig. 2, A and B). Statistical analysis revealed no 
signifi  cant difference in neurite length between the two geno-
types (P = 0.929).
In a parallel approach, we examined MAG inhibition of 
wild-type and p75
NTR−/− dorsal root ganglion (DRG) neurons. 
On CHO control cells, the neurite length of wild-type (79.9 ± 
2.5 μm) and p75
NTR−/− (78.6 ± 2.8 μm) DRG neurons is 
comparable. Consistent with previous studies (Wang et al., 
2002; Yamashita et al., 2002), we found that postnatal DRG 
neurons from p75
NTR mutants (64.8 ± 1.8 μm) are disinhib-
ited on MAG compared with wild-type controls (53.4 ± 1.7 
μm; Fig. 2, C and D). The disinhibition of p75
NTR−/− neurons 
is statistically signifi  cant (P < 0.001) but still incomplete, 
and fi  ber length is decreased compared with CHO control 
cultures. Previously, it was reported that CGNs of p75
NTR−/− 
and wild-type mice show strong and comparable inhibition 
on crude CNS myelin (Zheng et al., 2005). To expand on this 
study, we examined the importance of p75
NTR in the MAG-
mediated inhibition of CGNs. On CHO-MAG cells, wild-type 
(14.4 ± 0.7 μm) and p75
NTR-defi  cient (12.0 ± 0.4 μm) CGNs 
are both strongly inhibited (Fig. S2, A and B; available 
at http://www.jcb.org/cgi/content/full/jcb.200702102/DC1). 
On CHO cells, the neurite length of wild-type (28.3 ± 1.0 μm) 
and p75
NTR−/− (30.7 ± 0.8 μm) CGNs is comparable. Impor-
tantly, in the presence of the Rho kinase inhibitor Y27632 or 
dibutyryl-cAMP, the MAG inhibition of p75
NTR-defi  cient 
CGNs is completely released (Fig. S2 B). Together, our fi  nd-
ings suggest that MAG inhibits the growth of RGCs and 
CGNs through activation of the RhoA pathway in a p75
NTR-
independent manner.
Figure 2.  Limited role for the TNF receptor family members 
p75
NTR and TROY in MAG inhibition. (A–D) P7–10 RGCs 
(A) and P14 DRGs (C) from wild-type (p75
NTR+/+; white bars) 
and mutant (p75
NTR−/−; striped bars) littermates were plated 
on CHO or CHO-MAG feeder layers. (E and F) P8 wild-type 
(TROY
+/+; white bars) or mutant (TROY
−/−; striped bars) 
RGCs plated on CHO or CHO-MAG cells. (B, D, and F) 
Quantiﬁ  cation of the neurite length of TuJ1-stained cultures. 
The number of neurites measured for each condition is indi-
cated in parentheses. Results are presented as mean neurite 
length ± SEM (error bars). One-way analysis of variance with 
post-hoc pairwise comparisons (Dunn’s method). *, P < 
0.001. Bars (A and E), 25 μm; (C), 50 μm.JCB • VOLUME 177 • NUMBER 3 • 2007  396
In RGCs, TROY is not a functional 
substitute for p75
NTR
Although p75
NTR is strongly expressed in postnatal CGNs, there 
is little, if any, p75
NTR present in postnatal and adult RGCs 
 either  in  steady state (Hu et al., 1998) or after optic nerve injury 
(Hu et al., 1999; Hirsch et al., 2000). In neurons that lack 
p75
NTR, the TNF receptor family member TROY has been pro-
posed to serve as a functional substitute (Park et al., 2005; Shao 
et al., 2005). Because TROY is expressed in RGCs (Park et al., 
2005), we asked whether TROY-defi  cient RGCs are less responsive 
to MAG inhibition. As shown in Fig. 2 (E and F), neurite out-
growth of RGCs isolated from P8 TROY mutant (10.4 ± 0.8 μm) 
and wild-type (10.8 ± 0.8 μm) pups is strongly inhibited by 
MAG. No signifi  cant difference in neurite length was observed 
between TROY
−/− (34.4 ± 2.4 μm) and wild-type (32.2 ± 1.8 μm) 
RGCs plated on CHO cells (P = 0.305). In a parallel experi-
ment, we examined the MAG responsiveness of CGNs isolated 
from TROY
−/− mice and found no signifi  cant release of growth 
inhibition (P = 0.689; Fig. S2, C and D). Together, these fi  nd-
ings suggest that TROY does not serve as a functional substitute 
for p75
NTR in RGCs and is not necessary to bring about MAG 
inhibition in RGCs or CGNs.
Combined loss of NgR1 and terminal sialic 
acids attenuates MAG inhibition of RGCs
Next, we assessed the role of NgR1 in the MAG-mediated inhi-
bition of RGCs (Fig. 3). When plated on CHO cells, neurite out-
growth of wild-type RGCs (29.5 ± 1.8 μm) and NgR1
−/− RGCs 
(24.7 ± 1.4 μm) is robust, but NgR1
−/− RGC neurite length is 
decreased by 16.3% compared with wild-type littermate con-
trols. Although there was a statistically signifi  cant difference 
between wild-type and NgR1
−/− RGC neurite outgrowth on 
control CHO cells (P = 0.006), the percent outgrowth inhibition 
of wild-type (57%) and NgR1
−/− RGCs (60%) on CHO-MAG 
cells is very similar (Fig. 3 B). On CHO-MAG cells, the neurite 
length of NgR1
−/− RGCs (9.8 ± 0.7 μm) is decreased compared 
with wild-type RGCs (12.0 ± 0.8 μm; Fig. 3 C), suggesting that 
the reduced growth of NgR1
−/− RGCs is substrate independent. 
Thus, compared with wild-type RGCs, NgR1
−/− RGCs do not 
display enhanced fi  ber growth in the presence of MAG.
To expand on this observation, we considered the possi-
bility that MAG uses multiple and perhaps independent path-
ways to signal growth inhibition. Consistent with this idea, we 
found that the combined loss of terminal sialic acids and NgR1 
in RGCs leads to a signifi  cant increase in neurite length on 
CHO-MAG cells compared with untreated controls (Fig. 3 C). 
On CHO-MAG cells, the neurite length of NgR1-null RGCs in-
creases signifi  cantly from 9.8 ± 0.7 to 14.1 ± 1.2 μm after 
VCN treatment (P = 0.036). MAG inhibition of wild-type 
RGCs treated with VCN is not signifi  cantly attenuated (P = 
0.108). Importantly, the release of MAG inhibition of NgR1-
 defi  cient neurons treated with VCN is signifi  cant but not com-
plete. This suggests the existence of additional mechanisms for 
MAG inhibition in RGCs. Importantly, in the presence of the 
Rho kinase inhibitor Y27632 or dibutyryl-cAMP, MAG inhibi-
tion of RGCs is fully released (Fig. S3, available at http://www
.jcb.org/cgi/content/full/jcb.200702102/DC1). Together, our data 
imply that there are multiple and independent pathways for 
MAG to bring about neurite outgrowth inhibition in RGCs.
Cell type–speciﬁ  c mechanisms 
for MAG inhibition
In this study, we used a mouse genetic approach combined with 
the enzymatic removal of terminal sialic acid moieties to dissect 
the molecular composition of the neuronal receptor complex 
that signals MAG inhibition. The principal fi  ndings of our study 
Figure 3.  Loss of terminal sialic acids un-
masks a role for NgR1 in MAG inhibition. 
(A) P7–10 RGCs from wild-type (NgR1
+/+; 
white bars) or mutant (NgR1
−/−; striped bars) 
mice were cultured on CHO or CHO-MAG cells 
in the presence or absence of VCN and stained 
with TuJ1. (B) Quantiﬁ   cation of the neurite 
length of cultures not treated with VCN re-
vealed no difference in MAG inhibition be-
tween  NgR1
−/− and wild-type RGCs. (C) 
Quantiﬁ   cation of the neurite length of VCN-
treated cultures revealed an additive effect of 
VCN and the loss of NgR1
−/− in overcoming 
MAG inhibition. The number of neurites meas-
ured for each condition is indicated in paren-
theses. Results are presented as mean neurite 
length ± SEM (error bars). One-way analysis 
of variance with post-hoc pairwise comparisons 
(Holm-Sidak method). *, P < 0.05. Bar, 25 μm.ANALYSIS OF THE MAG RECEPTOR • VENKATESH ET AL. 397
are as follows: (1) loss of terminal sialic acids in CGNs but not 
RGCs is suffi  cient to attenuate MAG inhibition; (2) in DRG 
neurons but not in RGCs or CGNs, p75
NTR is important for 
MAG-elicited inhibition; (3) TROY-defi  cient RGCs and CGNs 
are strongly inhibited by MAG; and (4) loss of NgR1 in RGCs 
is not suffi  cient to attenuate MAG inhibition, but the combined 
loss of NgR1 and terminal sialic acids in RGCs attenuates MAG 
inhibition. Based on these observations, we conclude that MAG 
uses distinct and cell type–specifi  c mechanisms to signal neu-
rite outgrowth inhibition.
The neuronal distribution of receptor components impli-
cated in MAG inhibitory signaling is distinct and only partially 
overlapping (Pioro and Cuello, 1990a,b; Lauren et al., 2003; 
Park et al., 2005; Venkatesh et al., 2005; Barrette et al., 2007; 
Satoh et al., 2007). When coupled with previous fi  ndings that 
MAG inhibits a broad spectrum of postnatal neurons (DeBellard 
et al., 1996), this implies the existence of distinct and perhaps 
cell type–specifi  c mechanisms for MAG inhibition. Initially, 
our studies focused on RGCs, a population of heavily myelin-
ated neurons. Remarkably, neither the loss of sialoglycans nor 
individual components of the NgR1 receptor complex alone is 
suffi  cient to overcome MAG inhibition in RGCs. Interestingly, 
when combined with VCN treatment, the loss of NgR1 in RGCs 
leads to a signifi  cant disinhibition on MAG substrate (P = 
0.036). The release of inhibition in VCN-treated NgR1
−/− RGCs 
is still incomplete when compared with CHO control cultures. 
We conclude that neither the selective loss of NgR1 nor the en-
zymatic cleavage of sialoglycans alone is suffi  cient to overcome 
MAG inhibition of RGCs. When combined, however, enzy-
matic removal of terminal sialic acids unmasks a contribution 
of NgR1 in MAG inhibition. This suggests that NgR1 and sialo-
glycans function independently and in redundant signaling 
pathways to bring about MAG inhibition.
Nogo receptors and terminal sialic acids 
participate in MAG inhibition
Select gangliosides and the neuronal glycoproteins NgR1 and 
NgR2 have been shown to support MAG binding in a sialic 
acid–dependent manner. Functional studies revealed that CGNs 
treated with VCN or CGNs isolated from mice defi  cient for 
complex gangliosides are more resistant to MAG inhibition 
(DeBellard et al., 1996; Vyas et al., 2002). Previously, it has 
been found that the fi  rst three Ig repeats of MAG bind to neu-
rons in a sialic acid–dependent manner but are not suffi  cient to 
inhibit growth (Tang et al., 1997).
In spite of the broad distribution of MAG-binding ganglio-
sides, we fi  nd that enzymatic removal of terminal sialic acids is 
not suffi  cient to attenuate the MAG inhibition of RGCs. This is 
in marked contrast to CGNs, a neuronal cell type in which the 
enzymatic removal of terminal sialic acids substantially attenu-
ates MAG inhibition (Vyas et al., 2002). The differences in 
MAG inhibition observed between VCN-treated CGNs and 
RGCs is unexpected and suggests that MAG uses cell type–
 specifi  c mechanisms to bring about inhibition. When compared 
with RGCs, CGNs are a population of largely unmyelinated 
neurons that express low levels of NgR1 and lack NgR2 pro-
tein expression (Venkatesh et al., 2005; Zheng et al., 2005). 
This suggests that Nogo receptors play a minor role, if any, in 
the MAG-mediated inhibition of CGNs. In RGCs, however, 
NgR1 and NgR2 are more abundantly expressed, providing a 
potential explanation for why the selective loss of terminal si-
alic acids in RGCs is not suffi  cient to attenuate MAG inhibition. 
In this model, NgR1 and NgR2 would have to participate in 
MAG inhibition in the absence of terminal sialic acids. Consis-
tent with this idea, NgR1 and NgR2 both harbor multiple MAG 
docking sites, including sialic acid–dependent as well as sialic 
acid–independent sites (Venkatesh et al., 2005). We propose 
that in the presence of VCN, sialic acid–independent mecha-
nisms of NgR1 and NgR2 are suffi  cient to bring about MAG in-
hibition. Furthermore, the incomplete release of MAG inhibition 
in VCN-treated NgR1-null RGCs may be a refl  ection of NgR2-
dependent mechanisms. Consistent with the fi  nding  that 
p75
NTR−/− and TROY
−/− RGCs are still inhibited by MAG, NgR2 
does not support the binding of p75
NTR or TROY (unpublished 
data), suggesting novel, as yet unidentifi  ed signal transduction 
mechanisms for NgR2. Future studies are needed to determine 
whether the loss of MAG-binding gangliosides combined with the 
functional ablation of NgR1 and NgR2 is suffi  cient to fully over-
come MAG inhibition in RGCs and other neuronal cell types.
Limited role of the TNF receptor 
family members p75
NTR and TROY 
in MAG inhibition
The transmembrane-spanning proteins Lingo-1, p75
NTR, and 
TROY have been identifi  ed as the signal transducing compo-
nents in the NgR1 receptor complex. Upon MAG binding to the 
neuronal cell surface, p75
NTR undergoes regulated intramem-
brane proteolysis, and release of the intracellular domain of 
p75
NTR is important for RhoA activation and inhibition of neu-
rite outgrowth (Domeniconi et al., 2005). Our functional studies 
with p75
NTR-defi  cient neurons revealed that p75
NTR is important 
in DRG neurons but not in RGCs or CGNs for MAG inhibition 
(Figs. 2 and S2). This suggests a more limited and cell type–
specifi  c requirement for p75
NTR. Commensurate with this obser-
vation, an independent study (Zheng et al., 2005) found that 
p75
NTR-defi  cient DRG neurons are more resistant to CNS my-
elin inhibition than wild-type littermate controls. Under similar 
experimental conditions, no difference in inhibition between 
CGNs of wild-type and p75
NTR-defi  cient mice was observed 
(Zheng et al., 2005). In the present study, we expand on these 
fi  ndings by showing that p75
NTR in DRG neurons but not in 
CGNs participates in MAG inhibition. It is of interest that 
p75
NTR−/− CGNs are disinhibited on Nogo66 but not on MAG 
substrate (Zheng et al., 2005), This suggests that Nogo66 and 
MAG use distinct receptor systems to bring about growth inhi-
bition. Because CGNs do not express the MAG-specifi  c recep-
tor NgR2, the mechanism used by MAG to inhibit the growth of 
p75
NTR−/− CGNs is unknown.
RGCs express low levels of p75
NTR, and, after injury to the 
optic nerve, p75
NTR is not up-regulated in RGCs (Hu et al., 1998, 
1999; Hirsch et al., 2000). Consistent with this, RGCs from 
p75
NTR mice are strongly inhibited by MAG. TROY is expressed 
in RGCs and has been proposed to serve as a functional substitute 
in neurons that lack p75
NTR (Park et al., 2005; Shao et al., 2005). JCB • VOLUME 177 • NUMBER 3 • 2007  398
However, similar to wild-type controls, TROY
−/− RGCs are 
strongly inhibited by MAG. This suggests that in RGCs, TROY 
does not serve as a functional substitute for p75
NTR, a cell type 
that normally lacks p75
NTR expression. Consistent with our 
functional studies, it was recently reported that TROY has a re-
stricted neuronal expression in the adult mouse CNS (Barrette 
et al., 2007).
Implications for axonal regeneration 
after CNS injury
Commensurate with its pleiotropic effects, a growing number of 
MAG receptors has been identifi  ed. However, their relative con-
tribution to MAG-elicited outgrowth inhibition has not yet been 
examined systematically. In this study, we provide evidence for 
cell type–specifi  c mechanisms for MAG-elicited growth inhibi-
tion, an observation that may have important implications for 
the development of strategies aimed at overcoming the growth 
inhibitory barrier of adult CNS myelin. We propose that depend-
ing on the CNS fi  ber tracts injured, cell type–specifi  c strategies 
may be needed to promote axonal growth and regeneration. 
It has not yet been examined whether other myelin inhibitors, 
including Nogo-A and OMgp, use cell type–specifi  c mecha-
nisms to inhibit neuronal growth. The lack of robust regenera-
tive growth in spinal cord–injured mice with germline ablation 
of individual receptor components (Kim et al., 2004; Song 
et al., 2004; Zheng et al., 2005; Cafferty and Strittmatter, 2006) 
or myelin inhibitory proteins (Bartsch et al., 1995; Kim et al., 
2003; Simonen et al., 2003; Zheng et al., 2003) suggests that 
multiple and at least partially redundant mechanisms exist to 
bring about CNS myelin inhibition. Our studies also provide 
  evidence that within a specifi  c neuronal cell type, multiple and 
partially redundant pathways contribute to MAG inhibition. 
Based on these fi  ndings, the existence of one major cell surface 
receptor system that serves as a convergence point for multiple 
myelin inhibitors appears unlikely. Additional studies are needed 
to determine whether the combined loss of multiple receptors or 
the ablation of multiple growth inhibitors leads to a more robust 
neuronal growth response in vitro and after CNS injury in vivo.
Materials and methods
Mice and neurite outgrowth assays
Mice mutant for NgR1 (provided by M. Tessier-Lavigne, Genentech, South 
San Francisco, CA; Zheng et al., 2005), p75
NTR (provided by H. Federoff, 
Aab Institute for Biomedical Research, Rochester, NY; Lee et al., 1992), 
and TROY (Shao et al., 2005) have been described previously. To assay 
MAG-mediated growth inhibition, primary neurons were cultured on con-
ﬂ  uent monolayers of CHO cells that either express recombinant long MAG 
on their surface or on CHO cells lacking long MAG (Mukhopadhyay et al., 
1994). P7–8 rat and mouse CGNs were puriﬁ  ed in a discontinuous Percoll 
gradient (Hatten, 1985). P14 mouse DRG neurons were dissected and in-
cubated in 0.05% trypsin and 0.1% collagenase, triturated, and cultured 
in SATO
+ medium for 18–20 h (Venkatesh et al., 2005). RGCs were iso-
lated by anti-Thy1 immunopanning (Barres et al., 1988). In brief, P7–10 
rat or mouse retina was dissected in DME (Cellgro). Retinae were digested 
in 2 ml DME and 30 μl papain solution (10 U/ml; MP Biomedicals) for 
30 min at 37°C. The papain was removed by three washes in DME/10% FBS. 
The cell suspension was then plated onto 60-mm nontissue culture-coated 
Petri dishes that were precoated with goat anti–mouse IgG (Jackson Immuno-
Research Laboratories) and anti-Thy1.1 (Serotec, Inc.) for rat or goat 
anti–mouse IgM (Chemicon) and with anti-Thy1.2 (Sigma-Aldrich) for 
mouse RGCs. After a 1-h incubation at room temperature, unbound cells 
were removed by several rinses in PBS. Bound cells were lifted using 
0.125% trypsin/EDTA and were washed three times in DME/10% FBS. 
Cells were resuspended in SATO
+ medium, plated on CHO feeder layers, 
and cultured for 20–24 h before ﬁ  xation (Venkatesh et al., 2005). Rho 
  kinase inhibitor (Y27632; Calbiochem), dibutyryl-cAMP (Sigma-Aldrich), 
and VCN (Calbiochem) were used at the concentrations indicated and 
  directly added to the culture medium at the time of plating. VCN preferen-
tially cleaves α2-3–, α2-6–, and, to a lesser extent, α2-8–linked terminal 
  sialic acids. The loss of sialic acids in VCN-treated neurons results in a 
molecular weight shift of NgR1 that was assessed by immunoblotting as 
described previously (Venkatesh et al., 2005).
Quantitative analysis of neurite length
Quantiﬁ  cation of neurite outgrowth was performed as described previously 
(Venkatesh et al., 2005). In brief, cultures were ﬁ   xed in 4% PFA and 
blocked in 1% horse serum and 0.1% Triton X-100 in PBS, and neurons 
were stained with anti–class III β-tubulin antibody (TuJ1; Promega). Images 
were taken using an inverted microscope (IX71; Olympus) attached to a 
digital camera (DP70; Olympus), and neurite length was quantiﬁ  ed using 
UTHSCSA ImageTool for Windows. For quantiﬁ  cation of neurite outgrowth, 
processes equal or longer to approximately one cell body diameter were 
measured. For all experiments, the mean and SEM of neurite length was 
determined from multiple independent experiments. Several independent 
experiments were performed for quantiﬁ  cation of the neurite length of pri-
mary neurons isolated from the following mice: p75
NTR mice (DRGs, n = 3 
[+/+] and n = 3 (−/−); CGNs, n = 5 [+/+] and n = 5 [−/−]; and 
RGCs, n = 6 [+/+] and n = 8 [−/−]), TROY mice (RGCs, n = 3 [+/+] 
and n = 3 [−/−]; and CGNs, n = 2 [+/+] and n = 3 [−/−]), and NgR1 
mice (RGCs, n = 5 [+/+] and n = 4 [−/−]). For quantiﬁ  cation of the 
neurite length of mouse RGCs treated with 5 mU VCN, several indepen-
dent experiments were performed: n = 5 (NgR1
+/+) and n = 4 (NgR1
−/−). 
RGCs from NgR1 wild-type (+/+) and heterozygous (+/−) mice behave 
similarly in neurite outgrowth assays and were included as controls in some 
experiments. All data were analyzed using one-way analysis of variance 
followed by Dunn’s or Holm-Sidak post-hoc comparisons. All statistics were 
performed using SigmaStat 3.0 for Windows (Systat Software).
Online supplemental material
Fig. S1 shows that the loss of cell surface sialic acid moieties on feeder 
cells does not alter neuronal growth behavior. Fig. S2 shows that p75
NTR 
and TROY are not necessary for MAG-mediated inhibition of CGNs. Fig. 
S3 shows that MAG inhibition of RGCs is released in the presence of Rho 
kinase inhibitor or dibutyryl-cAMP. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200702102/DC1.
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